Bentiromide
Script error: No such module "redirect hatnote". Template:Chembox
Bentiromide is a peptide used as a screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy. Bentiromide is not available in the United States or Canada; it was withdrawn in the US in October 1996.[1]
Side effects
Headache and gastrointestinal disturbances have been reported in patients taking bentiromide.[1]
Mechanism of action
Bentiromide is given by mouth as a noninvasive test. It is broken down by the pancreatic enzyme chymotrypsin, yielding p-aminobenzoic acid (PABA). The amount of PABA and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas.
Chemistry
- XLogP=3.201
- H_bond_donor=4Template:Fact
- H_bond_acceptor=5Template:Fact
Synthesis
It is synthesized by amide formation between ethyl p-aminobenzoate and N-benzoyl-tyrosine using N-methyl-morpholine and ethyl chlorocarbonate for activation. The resulting L-amide is selectively hydrolyzed by sequential use of dimsyl sodium (NaDMSO) and dilute acid to give bentiromide (4).
See also
References
<templatestyles src="Reflist/styles.css" />
- ↑ a b Template:Drugs.com on bentiromide.
- ↑ P. L. De Benneville, N. J. Greenberger, <templatestyles src="Citation/styles.css"/>Template:Citation/make linkScript error: No such module "Check for unknown parameters".; eidem, U.S. patent 3801562 (1972, 1974 both to Rohm & Haas).
- ↑ Script error: No such module "Citation/CS1".
Script error: No such module "Check for unknown parameters".
Script error: No such module "Navbox".